|Chennai||Rs. 28730.00 (1.13%)|
|Mumbai||Rs. 29740.00 (-0.13%)|
|Delhi||Rs. 29200.00 (0%)|
|Kolkata||Rs. 29350.00 (0%)|
|Kerala||Rs. 28000.00 (0%)|
|Bangalore||Rs. 28400.00 (0%)|
|Hyderabad||Rs. 28470.00 (-0.11%)|
FDA OK: The Food and Drug Administration on Monday approved the drug Zytiga for a new group of prostate cancer patients who have not yet received chemotherapy.
FAMILIAR FACE: The FDA previously approved the pill from Johnson & Johnson for men with prostate cancer who have already taken the chemotherapy drug docetaxel.
HALTING HORMONES: Zytiga works be decreasing the male hormone testosterone, which spurs growth of prostate tumors.